1. Constitutional promoter methylation and risk of familial melanoma
- Author
-
Melissa Rotunno, Alisa M. Goldstein, Xiaolin Wu, Margaret A. Tucker, Ruth M. Pfeiffer, Paula L. Hyland, David Sun, Xiaohong Rose Yang, Laura S. Burke, and Prasad Patil
- Subjects
Adult ,Male ,Risk ,Cancer Research ,Skin Neoplasms ,Biology ,GPI-Linked Proteins ,Germline mutation ,CDKN2A ,Tumor Suppressor Protein p14ARF ,Receptors, Tumor Necrosis Factor, Member 10c ,medicine ,Humans ,Genetic Predisposition to Disease ,Epigenetics ,Promoter Regions, Genetic ,Melanoma ,neoplasms ,Molecular Biology ,Gene ,Genetic Association Studies ,Germ-Line Mutation ,Aged ,Genes, p16 ,Brief Report ,Promoter ,Methylation ,DNA Methylation ,Middle Aged ,medicine.disease ,Molecular biology ,Tumor Necrosis Factor Decoy Receptors ,Case-Control Studies ,DNA methylation ,Cancer research ,CpG Islands ,Female - Abstract
Constitutional epigenetic changes detected in blood or non-disease involving tissues have been associated with disease susceptibility. We measured promoter methylation of CDKN2A (p16 and p14ARF) and 13 melanoma-related genes using bisulfite pyrosequencing of blood DNA from 114 cases and 122 controls in 64 melanoma-prone families (26 segregating CDKN2A germline mutations). We also obtained gene expression data for these genes using microarrays from the same blood samples. We observed that CDKN2A epimutation is rare in melanoma families, and therefore is unlikely to cause major susceptibility in families without CDKN2A mutations. Although methylation levels for most gene promoters were very low (
- Published
- 2014